五种常用质子泵抑制剂前景及国内立项分析  

Prospects and project analysis of five commonly used proton pump inhibitors

作　　者：胡雅芳 邵秀芬 

机构地区：[1]杭州容立医药科技有限公司,浙江杭州310023

出　　处：《齐鲁药事》2011年第6期353-354,共2页qilu pharmaceutical affairs

摘　　要：消化性溃疡是一种常见病和多发病,质子泵抑制剂是目前治疗消化性溃疡病抑制胃酸分泌最为有效的药物,质子泵抑制剂的前景以及能否在国内立项是人们关注的热点。本文调研了五种常用质子泵抑制剂在国内外的上市情况,检索这些质子泵抑制剂在中国的专利状态并进行分析。结果表明,奥美拉唑、泮托拉唑、埃索美拉唑、雷贝拉唑和兰索拉唑(含右旋兰索拉唑)前景良好,其中有一些品种涉及专利问题,需注意。Peptic ulcer is a common and frequently-occurring disease.Proton pump inhibitor is the most powerful drug in inhibiting gastric acid secretion.Their prospects and whether the projects can be carried out were the focus of attention.This paper investigated listing status of five commonly used proton pump inhibitors at home and abroad,retrieved patents of the proton pump inhibitors in China and analyze the state.The results showed that Omeprazole,Pantoprazole,Esomeprazole,Rabeprazole and Lansoprazole（with dexlansoprazole） had good prospects,though some of them had patent issues which should be pay attention.

关 键 词：质子泵抑制剂 奥美拉唑 泮托拉唑 埃索美拉唑 雷贝拉唑 兰索拉唑 前景 立项 

分 类 号：R407.77[医药卫生—临床医学]